Clinical Trial Update: Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a pentavalent DTP-HB-Hib vaccine for immunogenicity and safety has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Disease
• Hepatitis B
• Pertussis
• Tetanus

Drugs mentioned

• DTP-HB-Hib vaccine (Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenzae type b conjugate vaccine (pentavalent))

Snippet

Sponsor: PT Bio Farma | Conditions: Diphtheria Vaccine Adverse Reaction, Tetanus Vaccine Adverse Reaction | Phase 3 | Status: WITHDRAWN